Literature DB >> 34023417

Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.

Hirotaka Komaba1, Takehiko Wada2, Masafumi Fukagawa2.   

Abstract

Entities:  

Year:  2021        PMID: 34023417      PMCID: PMC8137360          DOI: 10.1053/j.ajkd.2021.05.006

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


× No keyword cloud information.
To the Editor: We read with interest the recent reports , describing the development of minimal change disease (MCD) following the first injection of the BNT162b2 vaccine (Pfizer-BioNTech) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we report a case of nephrotic syndrome relapse in a patient with known MCD following the first injection of the Pfizer-BioNTech coronavirus 19 (COVID-19) vaccine. A man in his mid-sixties was followed up at our division for MCD, which was diagnosed by kidney biopsy when he developed nephrotic syndrome at the age of 40. He had been treated with prednisolone and cyclosporine; after long-term remission, the medications were tapered and discontinued 4 and 2 years prior, respectively. Recently, 8 days after receiving the first injection of the Pfizer-BioNTech vaccine, he noticed frothy urine. On the 19th day after vaccination, he visited our clinic, where laboratory tests revealed stable kidney function (serum creatinine 0.99 mg/dL), hypoalbuminemia (2.8 g/dL), and massive proteinuria (urinary protein-creatinine ratio, 11.48 g/g) with high selectivity (selectivity index 0.096), making a relapse of MCD the most likely diagnosis. As measured by the Elecsys immunoassay (Roche Diagnostics), the level of serum antibodies to the SARS-CoV-2 spike protein was markedly elevated (196 U/mL), indicating an immune response to vaccination. Prednisolone (20 mg/d) and cyclosporine (100 mg/d) were restarted, and his proteinuria resolved within 2 weeks (Fig 1).
Figure 1

Clinical course of the patient. Abbreviations: CyA, cyclosporine; PSL, prednisolone.

Clinical course of the patient. Abbreviations: CyA, cyclosporine; PSL, prednisolone. The Pfizer-BioNTech vaccine is reported to induce robust T-cell activation and cytokine release along with strong antibody responses, which might have contributed to MCD relapse in our patient. However, whether SARS-CoV-2 vaccines could trigger a relapse of MCD or other forms of nephrotic syndrome is currently unclear. Additional case reports and studies are required to address this important question.
  4 in total

1.  An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.

Authors:  Rutger J Maas; Sanne Gianotten; Wilbert A G van der Meijden
Journal:  Am J Kidney Dis       Date:  2021-05-13       Impact factor: 8.860

2.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

3.  Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.

Authors:  Larissa Lebedev; Marina Sapojnikov; Alexander Wechsler; Ronen Varadi-Levi; Doron Zamir; Ana Tobar; Nomy Levin-Iaina; Shlomo Fytlovich; Yoram Yagil
Journal:  Am J Kidney Dis       Date:  2021-04-08       Impact factor: 8.860

4.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.

Authors:  Ugur Sahin; Alexander Muik; Evelyna Derhovanessian; Isabel Vogler; Lena M Kranz; Mathias Vormehr; Alina Baum; Kristen Pascal; Jasmin Quandt; Daniel Maurus; Sebastian Brachtendorf; Verena Lörks; Julian Sikorski; Rolf Hilker; Dirk Becker; Ann-Kathrin Eller; Jan Grützner; Carsten Boesler; Corinna Rosenbaum; Marie-Cristine Kühnle; Ulrich Luxemburger; Alexandra Kemmer-Brück; David Langer; Martin Bexon; Stefanie Bolte; Katalin Karikó; Tania Palanche; Boris Fischer; Armin Schultz; Pei-Yong Shi; Camila Fontes-Garfias; John L Perez; Kena A Swanson; Jakob Loschko; Ingrid L Scully; Mark Cutler; Warren Kalina; Christos A Kyratsous; David Cooper; Philip R Dormitzer; Kathrin U Jansen; Özlem Türeci
Journal:  Nature       Date:  2020-09-30       Impact factor: 49.962

  4 in total
  17 in total

1.  Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases.

Authors:  Tiffany N Caza; Clarissa A Cassol; Nidia Messias; Andrew Hannoudi; Randy S Haun; Patrick D Walker; Rebecca M May; Regan M Seipp; Elizabeth J Betchick; Hassan Amin; Mandolin S Ziadie; Michael Haderlie; Joy Eduwu-Okwuwa; Irina Vancea; Melvin Seek; Essam B Elashi; Ganesh Shenoy; Sayeed Khalillullah; Jesse A Flaxenburg; John Brandt; Matthew J Diamond; Adam Frome; Eugene H Kim; Gregory Schlessinger; Erlandas Ulozas; Janice L Weatherspoon; Ethan Thomas Hoerschgen; Steven L Fabian; Sung Yong Bae; Bilal Iqbal; Kanwalijit K Chouhan; Zeina Karam; James T Henry; Christopher P Larsen
Journal:  Kidney360       Date:  2021-09-16

2.  New-onset and relapsing glomerular diseases related to COVID-19 vaccination.

Authors:  Fei Liu; Chunyue Feng; Jianhua Mao; Haidong Fu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

3.  A Case of Minimal Change Disease after SARS-CoV-2 Vaccination under the Age of 18.

Authors:  Mohamad Nour Alhosaini
Journal:  Avicenna J Med       Date:  2022-03-10

Review 4.  COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review.

Authors:  Naim Mahroum; Noy Lavine; Aviran Ohayon; Ravend Seida; Abdulkarim Alwani; Mahmoud Alrais; Magdi Zoubi; Nicola Luigi Bragazzi
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

5.  A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose.

Authors:  Reika Ikegami Mochizuki; Naohiro Takahashi; Ken Ikenouchi; Wakana Shoda; Tamaki Kuyama; Daiei Takahashi
Journal:  CEN Case Rep       Date:  2022-04-18

6.  A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine.

Authors:  Filipe S Mira; Jóni Costa Carvalho; Patrícia Amaral de Almeida; Ana Carolina Pimenta; Iolanda Alen Coutinho; Carolina Figueiredo; Luís Rodrigues; Vítor Sousa; Emanuel Ferreira; Helena Pinto; Luís Escada; Ana Galvão; Rui Alves
Journal:  Int J Nephrol Renovasc Dis       Date:  2021-12-03

7.  Reactivation of minimal change disease and IgA nephropathy after COVID-19 vaccination.

Authors:  Leanne Ca-Yin Leong; Wei-Zhen Hong; Priyanka Khatri
Journal:  Clin Kidney J       Date:  2021-12-01

8.  Minimal Change Disease After First Dose of Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Review of Minimal Change Disease Related to COVID-19 Vaccine.

Authors:  Jessica Hanna; Alistair Ingram; Tiffany Shao
Journal:  Can J Kidney Health Dis       Date:  2021-11-15

9.  Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD.

Authors:  Edward J Carr; Andreas Kronbichler; Matthew Graham-Brown; Graham Abra; Christos Argyropoulos; Lorraine Harper; Edgar V Lerma; Rita S Suri; Joel Topf; Michelle Willicombe; Swapnil Hiremath
Journal:  Kidney Int Rep       Date:  2021-07-06

10.  [Kidney damage in COVID-19].

Authors:  Stéphane Burtey; Marion Sallée
Journal:  Nephrol Ther       Date:  2021-06-23       Impact factor: 0.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.